Fierce Pharma

SEPTEMBER 13, 2024

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the medicine’s worth in patients whose cancer has spread to the b | To bolster Enhertu's case in HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo have rolled out positive data for the antibody-drug conjugate in patients (..)

Patients 276

Patients 276

Fierce Pharma

MARCH 5, 2024

A trial of Novo Nordisk's Ozempic on diabetes and kidney disease patients found that it reduced the risk of disease progression and death by 24%.

Patients 289

Patients 289

Fierce Pharma

APRIL 18, 2023

Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48

Biopharma 244

Biopharma Patients 244

Fierce Pharma

APRIL 6, 2023

Pfizer escapes proposed class action lawsuit over patient copay assistance esagonowsky Thu, 04/06/2023 - 11:03

Patients 260

Patients 260

Fierce Pharma

SEPTEMBER 26, 2023

As if the talc product liability lawsuits weren’t enough headache for Johnson & Johnson, the New Jersey pharma is now facing another lawsuit from patients, this time about a recent data breach. |

Patients 257

Patients Pharma 257

Fierce Pharma

MAY 9, 2024

While Vertex leads in patient starts, bluebird has activated more treatment centers. It’s not an easy question to answer.

Leads 246

Leads Patients FDA Pharmaceutical 246

Fierce Pharma

APRIL 27, 2023

Quitting Lilly's obesity drug tirzepatide may be difficult for many patients, exec says kdunleavy Thu, 04/27/2023 - 15:08

Patients 265

Patients 265

Fierce Pharma

APRIL 9, 2024

Medication adherence is a large and growing challenge for pharma companies, healthcare providers and the patients they serve. Research shows that 20% of patients have failed to fill a script in the past, and one-third aren’t confident managing their illness. Engaging patients from the moment a drug is prescribed can help.

Prescription 230

Prescription Patients Healthcare Provider Pharma 230

Fierce Pharma

OCTOBER 25, 2024

Johnson & Johnson tested Tremfya in patients with plaque psoriasis involvement in "sensitive or highly visible areas," while Lilly weighed Ebglyss in atopic dermatitis patients who've previously tried Dupixent.

Patients 229

Patients Competition Marketing 229

Fierce Pharma

SEPTEMBER 1, 2024

With the heart failure (HF) patient population rapidly expanding, the timing is right for Bayer’s Kerendia (finerenone). |

Patients 246

Patients 246

Fierce Pharma

JUNE 7, 2023

The rush to provide revolutionary weight-loss drugs to obese patients has reached the U.K. | The rush to provide revolutionary weight-loss drugs to obese patients has reached the U.K.

Patients 248

Patients Government 248

Fierce Pharma

SEPTEMBER 11, 2023

After 10 years of stagnation, a new FDA approval could help more cancer patients become eligible for stem cell transplants. |

FDA 235

FDA Patients 235

Fierce Pharma

NOVEMBER 13, 2023

Novo Nordisk has made a splash with its GLP-1 drugs that have allowed patients to achieve significant weight loss. Novo Nordisk has made a splash with its GLP-1 drugs that have allowed patients to achieve significant weight loss.

Patients 259

Patients 259

Fierce Pharma

SEPTEMBER 5, 2024

AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud case. AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud case.

Insurance 340

Insurance Patients 340

Fierce Pharma

SEPTEMBER 5, 2023

As the Federal Trade Commission (FTC) scrutinizes Pfizer’s $43 billion Seagen buyout, the antibody-drug conjugate (ADC) specialist has notched a phase 3 win that could broaden its cervical cancer a | The drug boosted overall survival, progression-free survival and objective response rates in patients with recurrent or metastatic cervical cancer who (..)

Patients 244

Patients 244

Fierce Pharma

OCTOBER 10, 2024

Now, with new data indicating the drug could prolong patients’ lives, the company is targeting an even wider label. In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class.

Patients 215

Patients FDA 215

Fierce Pharma

JUNE 18, 2024

Authors: Arlene Pineda, Senior Director, Patient Support Services, IQVIA Kristina Jones, Principal, Patient Services Technology & Analytics, IQVIA | In a curious twist, patient support programs — often designed to alleviate the burden on patients — sometimes create unintended challenges.

Patients 166

Patients 166

Fierce Pharma

MARCH 17, 2023

Astellas, Pfizer look to broaden Xtandi’s patient base with new prostate cancer win after 8 years aliu Fri, 03/17/2023 - 10:22

Patients 237

Patients 237

Fierce Pharma

NOVEMBER 19, 2024

KnippeRx Transforms Patient Assistance Programs through Technology and Patient-Focused Solutions. jpiatt Tue, 11/19/2024 - 10:05

Patients 130

Patients 130

Fierce Pharma

AUGUST 24, 2023

mg dose bested placebo at reducing symptoms and physical limitations in patients with obesity and heart failure with preserved ejection fraction. Just a few short weeks after Wegovy posted a major cardio outcomes win, Novo Nordisk has chalked up another heart-related victory for its semaglutide star. |

Patients 243

Patients Medicine 243

Fierce Pharma

FEBRUARY 20, 2024

GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control. GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control.

Patients 197

Patients Medical 197

Fierce Pharma

JULY 6, 2023

GSK’s Cabenuva made history in 2020 as the world’s firs | GSK's long-acting Cabenuva is currently approved only as a switch therapy for patients who already have undetectable HIV levels in the blood. Trying to reach some tough populations who have difficulty adhering to existing daily oral therapies, GSK is getting creative.

Patients 241

Patients 241

Fierce Pharma

APRIL 14, 2023

AACR: Patient deaths taint Roche's industry-first early-stage liver cancer readout for Tecentriq and Avastin aliu Fri, 04/14/2023 - 22:19

Patients 224

Patients 224

Fierce Pharma

DECEMBER 5, 2023

Further, the group detailed the impact of the crisis on both adult and child cancer patients. . | In its letter to congressional leaders, the American Cancer Society Cancer Action Network (ACS CAN) outlined the root causes of drug shortages and offered potential solutions.

Patients 220

Patients Networking 220

Fierce Pharma

JULY 15, 2024

million gene therapy Casgevy for sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), patients must first undergo chemotherapy | Vertex has filed a lawsuit in federal court in Washington, D.C. To receive Vertex and CRISPR Therapeutics’ $2.2 against the U.S.

Patients 180

Patients 180

Fierce Pharma

MAY 24, 2024

While it’s hard to overstate the success Novo Nordisk’s GLP-1 franchise has already achieved, the company’s latest deep dive into semaglutide data in chronic kidney disease (CKD) could help set a n | Early Friday, Novo shared full, positive results from the FLOW trial assessing the ability of once-weekly semaglutide 1.0

Patients 314

Patients 314

Fierce Pharma

FEBRUARY 27, 2024

Delivering on these heightened expectations has fueled the urgency to invest in patient engagement and support. A seismic shift has occurred in the healthcare landscape.

Biopharma 178

Biopharma Patients Healthcare Healthcare 178

Fierce Pharma

AUGUST 27, 2024

Eli Lilly has come up with a new way of supplying its popular weight-loss drug Zepbound that the company hopes could expand access while addressing other issues such as high prices and off-label co | Eli Lilly is offering its popular weight-loss drug Zepbound directly to consumers at a discount through its own online pharmacy.

Patients 304

Patients 304

Fierce Pharma

OCTOBER 3, 2024

Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patient healthcare solution - sat down with Fierce at Digital Phar | Matthew Walsh, General Manager of Biopharma at Ixlayer – a cloud-based platform specialist empowering operational efficiency, patient access, and improved outcomes (..)

Patients 130

Patients Biopharma Management Pharma 130

Fierce Pharma

NOVEMBER 15, 2024

Azurity Pharmaceuticals has earned an FDA approval for Danziten, a new formulation of Novartis’ chronic myeloid leukemia (CML) blockbuster Tasigna.

FDA 235

FDA Patients Pharmaceutical 235

Fierce Pharma

JULY 25, 2023

Now, the partners have a clutch of data suggesting their long-acting injectable is popular among patients. . | To make Cabenuva the standard treatment option for HIV, Johnson & Johnson and GSK-owned ViiV Healthcare must first dethrone Gilead Sciences’ once-daily stalwart Biktarvy.

Patients 210

Patients Healthcare Healthcare 210

Fierce Pharma

MAY 31, 2024

When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal.

Patients 273

Patients 273